Personalized therapy for acute myeloid leukemia

Research output: Contribution to journalArticlepeer-review

Abstract

Patient-specific ex vivo drug sensitivity and resistance screening can identify rational drug candidates for the testing of personalized targeted therapy. An iterative approach of genomic and drug susceptibility characterization at sequential time points during clinical trials of targeted therapy in acute myeloid leukemia may be useful both for characterizing mechanisms of resistance and clonal evolution and also for identification of novel therapeutic targets and drug combinations.

Original languageEnglish (US)
Pages (from-to)1336-1338
Number of pages3
JournalCancer discovery
Volume3
Issue number12
DOIs
StatePublished - Dec 2013
Externally publishedYes

ASJC Scopus subject areas

  • Oncology

Fingerprint

Dive into the research topics of 'Personalized therapy for acute myeloid leukemia'. Together they form a unique fingerprint.

Cite this